Stockholm3 - Diagnosing prostate cancer

Artificial intelligence platform is capable of accurately diagnosing prostate cancer in tissue samples, offering the potential to speed up diagnostics and reduce costs for healthcare services The findings, published in The Lancet Oncology in December, suggest AI systems can be trained to detect and grade cancer in prostate needle biopsy samples with an accuracy rate equal to that of international prostate pathology experts. Furthermore, the study noted that the use of AI technology could help reduce the workload of oncologists by reducing the assessment of benign biopsies and by automating the task of measuring cancer length in positive biopsy cores, as well as providing a second opinion. in 2017, which is currently used in clinical practice in Sweden, Norway, Finland and Denmark.